|Description||RN983 is a selective BTK enzyme inhibitor. It inhibits IgG production in B-cells with an IC50 value of 2.5 ± 0.7 nM and PGD2 production from mast cells with an IC50 value of 8.3 ± 1.1 nM. RN983 showed similar activities in the allergic mouse model of asthma. RN983 may be effective as a stand-alone asthma therapy or used in combination with inhaled steroids and β-agonists in severe asthmatics.|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
CNX-774 is a potent Btk inhibitor (IC50 < 1 nM)
Btk inhibitor 1 R enantiomer hydrochlori
Btk inhibitor 1R enantiomer Hcl is a pyrazolo[3,4-d]pyrimidine derivative as a <strong>Btk </strong>kinase inhibitor.
GDC-0834 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis. In vitro metabol...
(-)-Terreic acid is a selective inhibitor of Bruton's tyrosine kinase (BTK) with antibiotic activity. (-)-Terreic acid inhibits the catalytic activity of BTK an...
ONO-4059, a BTK inhibitor, has been found to have potential effect against sorts of malignancies by influencing the B-cell development. It is currently under Ph...
Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. It inhibits the...
GDC-0834 is a small molecule inhibitor of Btk potentially useful in the treatment of RA and lymphoid malignancies. Administration of GDC-0834 (30 -- 100 mg/kg)...
BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability, achieving higher ...